Original Article

Overtreatment and Undertreatment of Hyperlipidemia in the Outpatient Setting

Authors: Ashish Verma, MD, Paul Visintainer, PhD, Mohamed Elarabi, MD, Siddharth Wartak, MD, Michael B. Rothberg, MD, MPH

Abstract

Background: National guidelines recommend lipid-lowering therapy for patients with coronary heart disease (CHD), its equivalent (eg, diabetes mellitus, peripheral arterial disease, cerebrovascular disease), and those at high risk of CHD. Quality-of-care studies demonstrate that patients at high risk of CHD are undertreated. Overtreatment of patients at low risk of CHD remains relatively unexplored. Our study aimed to determine patient characteristics associated with under- and overtreatment of hyperlipidemia.


Methods: We conducted a retrospective chart review of patients aged 35 to 80 years attending an inner-city ambulatory teaching clinic. We noted patients’ 10-year cardiovascular risk based on the Framingham Heart Study equation, other patient demographics, pretreatment lipid levels, and whether they received a prescription for lipid-lowering therapy.


Results: Of 676 patients included, 46% were at high (>15% for 10 years) and 37% were at low (<5%) risk. Of the patients at high risk for CHD, 34% received no drug therapy, including 5% of patients with known CHD; 37% of patients with diabetes mellitus; and 59% of patients without CHD equivalents. Undertreatment was associated with lower low-density lipoprotein (LDL; odds ratio [OR] per 30 mg/dL 2.7, confidence interval [CI] 2.0–3.6), fewer risk factors (OR per risk factor 1.5 CI 1.1–2.1), and not receiving other preventive care interventions (OR 2.1, CI 1.0–4.5). Of 247 patients at low risk for CHD, 8% received drug therapy. Overtreatment was associated with higher LDL (OR per 30 mg/dL 3.0, CI 1.7–5.3) and more cardiac risk factors (OR per risk factor 3.1, CI 1.4–6.7). Age, race, sex, and specific risk factors were not associated with overtreatment or undertreatment.


Conclusions: Both overtreatment and under-treatment are common. Physicians’ decisions appear to reflect LDL values and number of risk factors rather than calculated cardiovascular risk.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA 2009; 302: 2104–2110.
 
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
 
3. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–1839.
 
4. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.
 
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
 
6. Foody JM, Krumholz HM. Are statins indicated for the primary prevention of CAD in octogenarians? Antagonist viewpoint. Am J Geriatr Cardiol 2003; 12: 357–360.
 
7. National Heart Lung and Blood Institute. Framingham Heart Study: hard coronary heart disease: 10-year risk. http://www.framinghamheartstudy.org/risk/hrdcoronary.html. Accessed March 1, 2011.
 
8. Hayward RA, Krumholz HM, Zulman DM, et al. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 2010; 152: 69–77.
 
9. Choudhry NK. Copayment levels and medication adherence: less is more. Circulation 2009; 119: 365–367.
 
10. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people With diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114–126.
 
11. Abookire SA, Karson AS, Fiskio J, et al. Use and monitoring of “statin” lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53–58.
 
12. Gordon WJ, Polansky JM, Boscardin WJ, et al. Coronary risk assessment by point-based vs. equation-based Framingham models: significant implications for clinical care. J Gen Intern Med 2010; 25: 1145–1151.
 
13. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005; 293: 1223–1238.
 
14. Persell SD, Zei C, Cameron KA, et al. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Intern Med 2010; 170: 470–477.